Andere talen Eris Lifesciences Limited Bombay S.E.

Aandelen

ERIS

INE406M01024

Beurs gesloten - Bombay S.E. Andere beurzen 12:11:41 03-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
867 ^INR	-2,68%		-2,86%	-4,78%

03/04	Eris Lifesciences rondt overname af van de formuleringsactiviteiten van Biocon Biologics in India	MT
15/03	Eris Lifesciences neemt de Indiase formuleringsactiviteiten van Biocon Biologics over voor 12,42 miljard INR	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Eris Lifesciences Completes Acquisition of Biocon Biologics' India Formulation Business	03/04
Eris Lifesciences to Acquire India Formulation Business of Biocon Biologics for INR12.42 Billion	15/03
Eris to Acquire Additional Stake in Swiss Parenterals, Take Over Branded Formulations Business of Biocon Biologics	14/03
India's Biocon to sell branded formulations business to Eris Lifesciences for $150 million	14/03
Eris Lifesciences Limited agreed to acquire Biocon Biologics India Branded Formulations business for INR 12.42 billion.	14/03
Eris Lifesciences Completes Purchase of 51% Stake in Swiss Parenterals	16/02
Eris Lifesciences Limited completed the acquisition of 51% stake in Swiss Parenterals Limited.	15/02
Eris Lifesciences Limited Provides Earnings Guidance for the Fiscal 2025 and Fiscal 2026	13/02
Eris Lifesciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	13/02
Eris Lifesciences Limited agreed to acquire 51% stake in Swiss Parenterals Limited INR 6.4 billion.	13/02
India's Biocon posts profit on biosimilar boost, divestment gains; CFO resigns	08/02
Eris Lifesciences Limited completed the acquisition of Dermatology and Nephrology branded formulations business units of Biocon Biologics	10/11
Biocon Biologics Announces Divestment of Two Non-Core Branded Formulations, India Business Units	09/11
Indian shares set to open higher tracking Asian peers	09/11
Eris Lifesciences Limited Reaffirms Earnings Guidance for the Full Year of Fiscal 2024	08/11
Eris Lifesciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	08/11
Eris Lifesciences Limited entered into a definitive agreement to acquire Dermatology and Nephrology branded formulations business units of Biocon Biologics for INR 3.7 billion.	08/11
Eris Lifesciences Limited Enters into Term Loan Agreement to Avail the Rupee Term Loan Facility from HDFC Bank Limited	29-09-23
Eris Lifesciences Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	07-08-23
Eris Lifesciences Gains Dermatology Trademarks Acquired from Glenmark via Deal with Unit Eris Oaknet	04-07-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Eris Lifesciences Limited Bombay S.E.

Aandelen

ERIS

INE406M01024

Andere talen

Filters